Ranbaxy Lab gets nod to market Lisinopril in Canada

MUMBAI: Pharma Major Ranbaxy Laboratories on Monday said it has received approval from Canadian regulatory authority for marketing hypertension drug Lisinopril in the North American country.

Health Canada, Therapeutic Products Directorate, gave its approval for Ran - Lisinopril 5, 10 and 20 mg oral tablets, which has a market of 46 million Canadian Dollar(about Rs 189 crore).

The tablets would be manufactured under the current Good Manufacturing Practice Regulations (cGMP) promulgated by the US Food and Drug Administrations, the company said.
    
"Lisinopril will be manufactured in Ranbaxy's cGMP facility located in North Brunswick, New Jersey. This will expand Ranbaxy's product portfolio of accessible generic product offerings," Ranbaxy Pharmaceuticals President-Canada Inc Paul Drake said.

The product formulation was developed and data-assembled by Ranbaxy Laboratories Limited, the company informed the Bombay Stock Exchange.
    
Shares of the firm were trading at Rs 416.55, unchanged in the afternoon trade, at the BSE.